Novasep Invests 4 Million Euros to Expand its Cryogenic Production Capacity

Tuesday, October 24, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

Novasep announces €4M investment to install a new cryogenics production line and a new pilot stream at its Chasse-sur-Rhône (FR) facility

LYON, France, October 24, 2017 /PRNewswire/ --

Novasep, a leading supplier of services and technologies for the

life sciences industry, today announced a €4M investment to expand cGMP capacity for clinical and commercial supply of APIs at its Chasse-sur-Rhône (FR) facility.

The investment includes the installation of a new cGMP cryogenic production line, capable of operating at temperatures as low as -80°C. It is equipped with a 4m3 Hastelloy reactor, filter drier and clean room.

The investment also includes an expansion of the cGMP pilot-plant capabilities with the addition of a new stream comprising a 400L Hastelloy reactor, filter drier and clean room. This will add flexible small-scale manufacturing capacity and reinforce the site's capability to handle both clinical development needs and low volume APIs.

The investment will be operational by the beginning of 2018. Novasep's total low temperature capacity will then reach more than 35m3.

"By increasing cryogenics capacity at the current Chasse-sur-Rhône facility, we strengthen Novasep's small and large-scale volume offering for low temperature manufacturing." Jean-Pierre Pilleux, General Manager of the Chasse-sur-Rhône site said, "It will give us more flexibility and allow us to address the increasing market demand for these types of capabilities."

As a CDMO, Novasep has a 30-year track-record in the scale up, validation and commercial supply of low-temperature chemistry under cGMP. These new facilities will enable Novasep to handle highly reactive compounds such as organometallic reagents and improve the selectivity of reactions.

For press information, click here: https://www.novasep.com/press-release-about-novasep.html

SOURCE Novasep



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store